Insmed Incorporated

“the milestone payment to AstraZeneca related to BRINSUPRI's U.S. approval.”

Insmed made a milestone payment to AstraZeneca tied to BRINSUPRI's U.S. approval, reflecting the licensing relationship underpinning Insmed's now-launched flagship drug.

“the reopen trial, which was on with the Optinose exhale device, which is based on a steroid treatment”

Insmed references Optinose's exhale steroid device trial as the comparator/incumbent context for its brensocatib CRS-without-nasal-polyps program.

“Sotatercept, I think, came in around 33 or 35, so we edged that out, and it's a different kind of medicine, obviously, and it's not an apples-to-apples comparison”

Insmed benchmarks TPIP's 35.5% PVR reduction in PAH against Merck's sotatercept (~33-35%), positioning TPIP favorably on efficacy.

“given the progress United Therapeutics is showing. I'm just curious if maybe you can comment on how you would need to design that program to ensure your ability to launch it?”

United Therapeutics' advancing IPF/PPF program raises the question of orphan-drug exclusivity Insmed's TPIP would need to overcome in that indication.

“We set out four years ago when we bought Motus to give support to Bryan's vision that an intrathecal delivery route would improve safety and efficacy.”

Insmed acquired Motus about four years ago to build its intrathecal gene-therapy delivery platform, now its San Diego DMD/gene-therapy research site.

“We know how sotatercept is perceived and what a positive contribution that is to the disease state”

Insmed frames Merck's sotatercept (Winrevair) as a well-regarded PAH therapy it is designing its TPIP Phase III program around; sotatercept only addresses PAH, not PH-ILD where TPIP also competes.

“this max dose represents about 60% more treprostinil than the combination of four daily doses of TYVASO DPI”

Insmed benchmarks its TPIP maximum dose against United Therapeutics' TYVASO DPI, framing TPIP's dosing headroom relative to the existing competing treprostinil therapy.

“it's been for drugs like Dupixent and other extremely impactful medicines”

Insmed's CEO cites Dupixent as one of the rare drugs whose Phase 2 and Phase 3 results were both highlighted by the New England Journal of Medicine, framing it as a peer for highly impactful therapies.

“With the patient death reported with Sarepta's DMD gene therapy, has this influenced your development strategy at all?”

An analyst raises Sarepta's DMD gene therapy patient death as a safety concern relevant to the broader gene therapy field, including Insmed's own program.